Functional targeting of ILC2s and ILC3s reveals selective roles in intestinal fibrosis and homeostasis
Journal of Experimental Medicine · 07.07.2025 · 222 (7)
DOI: 10.1084/jem.20241671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 28.05.2025. Verfasst von Ahmed Kabil und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, University of British Columbia , Vancouver, Canada. Hauptthemen laut MEDLINE: Homeostasis, Immunity, Innate, Lymphocytes, Intestines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Microbiome Team Grants, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Innate lymphoid cells (ILCs) are long-lived, tissue-resident cell analogs to T helper subsets that lack antigen-specific receptors. Understanding the roles of specific ILCs in chronic inflammation and fibrosis has been limited by inadequate tools for selective targeting. Here, we used Il17rb-CreERT2-eGFP and Rorc-Cre strains to selectively delete RORα in ILC2s and ILC3/Th17 cells, respectively. RORα deletion in ILC2s caused significant loss of gastrointestinal ILC2s, increased ILC3 abundance, elevated Th17-type responses, and heightened susceptibility to Crohn’s disease–like fibrosis. Conversely, RORα deletion in ILC3/Th17 cells reduced IL-17 production, protecting against fibrosis. Using isolithocholic acid (isoLCA), a microbial secondary bile acid and RORγt inverse agonist, we confirmed the role of ILC3s/Th17 cells in fibrosis. In RORγt reporter and Th17-deficient Rag1−/− mice, isoLCA reduced IL-17 production by ILC3s and attenuated intestinal fibrosis by dampening RORγt-dependent ILC3/Th17 responses. These findings reveal a novel interplay between ILC2s and ILC3s in gut homeostasis and demonstrate the therapeutic potential of targeting RORγt in ILC3s as a strategy for preventing fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering, University of British Columbia , Vancouver, Canada.
- Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, Canada.
- Department of Pathology and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
- The Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
- The Center for Heart Lung Innovation, St Paul's Hospital , Vancouver, Canada.
ORCID-Profile: Ahmed Kabil, Natalia Nayyar, Chengxi Xu, Julyanne Brassard, Lesley A Hill, Samuel B Shin, Sameeksha Chopra, Bernard Lo, Yicong Li, Mya Bal, Marine Theret, Fabio M V Rossi, T Michael Underhill, Michael R Hughes, Kelly M McNagny
Förderung
- CIHR
- Canadian Microbiome Team Grants
- Natural Sciences and Engineering Research Council of Canada
- Michael Smith Foundation of Health Research
- Canadian Institutes of Health Research
Zitieren
APA
Kabil, A., Nayyar, N., Xu, C., Brassard, J., Hill, L. A., Shin, S. B., Chopra, S., Lo, B., Li, Y., Bal, M., Theret, M., Rossi, F. M. V., Underhill, T. M., Hughes, M. R., & McNagny, K. M. (2025). Functional targeting of ILC2s and ILC3s reveals selective roles in intestinal fibrosis and homeostasis. Journal of Experimental Medicine, 222(7). https://doi.org/10.1084/jem.20241671
Vancouver
Kabil A, Nayyar N, Xu C, Brassard J, Hill LA, Shin SB, et al. Functional targeting of ILC2s and ILC3s reveals selective roles in intestinal fibrosis and homeostasis. Journal of Experimental Medicine. 2025;222(7). doi:10.1084/jem.20241671
BibTeX
@article{Kabil2025,
author = {Kabil, Ahmed and Nayyar, Natalia and Xu, Chengxi and Brassard, Julyanne and Hill, Lesley A and Shin, Samuel B and Chopra, Sameeksha and Lo, Bernard and Li, Yicong and Bal, Mya and Theret, Marine and Rossi, Fabio M V and Underhill, T Michael and Hughes, Michael R and McNagny, Kelly M},
title = {Functional targeting of ILC2s and ILC3s reveals selective roles in intestinal fibrosis and homeostasis},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {7},
doi = {10.1084/jem.20241671}
}
EUVIMED